Close

AbbVie's (ABBV) Glecaprevir/Pibrentasvir HCV Regiment Receives FDA Breakthrough Therapy Designation

September 30, 2016 8:01 AM EDT Send to a Friend
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login